FICHA DEL DOCTOR

Dr. JP Maroto Rey

Publicaciones

Revistas científicas

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. (ver web)

(coautores junto a González JL, Prior C, Castellano D, Mellado B, Gallardo E, Perez JL,, Villanueva X, Albanell J, Calvo A).  Ann Oncol. 2011 Mar 21.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. (ver web)

(coautores junto a González-Larriba JL, Prior C, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A). Epub 2011 Mar 21.

Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. (ver web)

(coautor junto a Aparicio J, del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR).J Clin Oncol. 2011 Dec 10;29(35):4677-81. Epub 2011 Oct 31.

Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors. (ver web)

(coautor junto a Huddart R, Garcia del Muro X, Horwich A, Paz Ares L, Aparicio J, Germa-Lluch JR). Oncology. 2011;80(3-4):219-22. Epub 2011 Jul 4.